Lntravesical Instillation of Mitomycin C in the Prophylactic Treatment of Recurring Superficial Transitional Cell Carcinoma of the Bladder*

Abstract

Patients (26) with an elevated recurrence rate of stage O or A bladder tumors were treated prophylactically after transurethral resection (TRU) with short-term intravesical instillations of mitomycin C in a non-randomized study. The data before intravesical chemotherapy (IVC) were taken as the internal control for each patient. Mitomycin C was administered in 1 course of 10 daily doses of 40 mg, starting 24-48 h after TUR. The average follow-up was 13.9 mo. before and 28.5 mo. after IVC. Before IVC, the average number of recurrences was 2.6, with an average recurrence rate of 1 every 5.3 mo. After IVC there was no tumor recurrence in 4 patients, with a mean of 12.2 mo. follow-up, but there was tumor recurrence in 22 patients. For 17 patients (77%) the free interval averaged 2.3 times longer than the mean interval of recurrence before IVC and for 18 patients (82%) the recurrence rate averaged 3.3 times less than the recurrence rate before IVC.